title: Functional analysis of CD8 lymphocytes in long-term surviving patients after bone marrow transplantation.
abstract: The recovery of T-cell populations after bone marrow transplantation (BMT) is characterized by a persistent expansion of CD8 lymphocytes. Previously, we have shown that beyond 1 year posttransplantation the CD8 lymphocytes consist, to a large extent, of CD8+ HNK1+ cells that suppress, like normal CD8 lymphocytes, immunoglobulin production in vitro. We have further investigated the functional capabilities of CD8 lymphocytes, mostly HNK1+ (from 50 to 77%), in seven long-term BMT patients. As normal, patient CD8 lymphocytes do not suppress (1) phytohemagglutinin (PHA)-induced interleukin 2 (IL2) receptor expression and IL2 responsiveness by normal T cells or (2) the mixed lymphocyte reaction of donor cells. Also as normal, patient CD8 lymphocytes can be activated into potent cytotoxic effectors. Therefore, under the present experimental conditions, the increase in the absolute number of CD8 lymphocytes in the long-term BMT patients is characterized by an expansion of the CD8+ HNK1+-cell subpopulation and a normal suppressor/cytotoxic potential on a per-CD8+ cell basis.
authors.affiliation: INSERM U.91, Hôpital Henri Mondor, Créteil, France.
authors.forename: M
authors.initials: M
authors.lastname: Divine
authors.forename: J P
authors.initials: JP
authors.lastname: Lecouedic
authors.forename: M F
authors.initials: MF
authors.lastname: Gourdin
authors.forename: N
authors.initials: N
authors.lastname: Oudhriri
authors.forename: M
authors.initials: M
authors.lastname: Zohair
authors.forename: T
authors.initials: T
authors.lastname: Henni
authors.forename: F
authors.initials: F
authors.lastname: Beaujan
authors.forename: J P
authors.initials: JP
authors.lastname: Vernant
authors.forename: F
authors.initials: F
authors.lastname: Reyes
authors.forename: J P
authors.initials: JP
authors.lastname: Farcet
mesh_terms: D001853:Bone Marrow / Q000276:immunology; D016026:Bone Marrow Transplantation; D006801:Humans; D007938:Leukemia / Q000628:therapy; D008213:Lymphocyte Activation; D007959:Lymphocyte Culture Test, Mixed; D011948:Receptors, Antigen, T-Cell / Q000032:analysis; D011971:Receptors, Immunologic / Q000032:analysis; D015375:Receptors, Interleukin-2; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D006377:T-Lymphocytes, Helper-Inducer / Q000166:cytology; D050378:T-Lymphocytes, Regulatory / Q000166:cytology / Q000276:immunology*
chemical_list: D011948:Receptors, Antigen, T-Cell; D011971:Receptors, Immunologic; D015375:Receptors, Interleukin-2